On September 4, 2025, Sangamo Therapeutics reported updated clinical data from their Phase 1/2 STAAR study of ST-920, a gene therapy for Fabry disease, indicating positive mean annualized eGFR slopes of approximately 1.97 mL/min/1.73m²/year across 33 treated patients as of April 10, 2025, while preparing for a Biologics License Application submission in early 2026, subject to funding.